



Gp 1642

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant

Gregg B. Fields, et al.

Group Art Unit: 1642

Serial No.:

09/529,691

Examiner: S. Rawlings

Filed:

August 29, 2000 (Int'l Filing Date: Oct. 22, 1998)

Docket No.: 110.00680101

Title:

INHIBITION OF TUMOR CELL ADHESION TO TYPE IV COLLAGEN

Assistant Commissioner for Patents  
**BOX SEQUENCE**  
Washington, D.C. 20231

We are transmitting the following documents along with this Transmittal Sheet:

**Small entity status is entitled to be asserted in the above-identified application.**

A return postcard.

A Petition for Extension of Time for \_\_\_ month(s) and a check in the amount of \$\_\_\_ for the required fee.

An Information Disclosure Statement (\_\_\_ pgs); copies of \_\_\_ applications; 1449 forms (\_\_\_ pgs); and copies of \_\_\_ documents cited on the 1449 forms.

A check in the amount of \$\_\_\_, representing \_\_\_.

Preliminary Amendment and Response to Notice to Comply with Sequence Requirements (4 pgs total, including Appendix A (1 pg); Sequence Listing (2 pgs); Computer-readable version of Sequence Listing (1 diskette); Copy of Notice to Comply with Requirements.

Other:

Amendment      \_\_\_ No Additional fee is required.      \_\_\_ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$40 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$135 Here →					
Total Additional Claim Fees Required					

Please consider this a **PETITION FOR EXTENSION OF TIME** for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

**CERTIFICATE UNDER 37 C.F.R. §1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, BOX SEQUENCE, Washington, D.C. 20231, on this 30th day of April, 2001.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813

By: David L. Provence  
Name: David L. Provence  
Reg. No.: 43,022  
Direct Dial: 612-305-1005  
Facsimile: 612-305-1228

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.8)

TECH CENTER 1600/2900

MAY 07 2001

RECEIVED



RECEIVED

MAY 07 2001

TECH CENTER 1600/2900

PATENT  
Docket No. 110.00680101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gregg B. Fields, et al. ) Group Art Unit: 1642  
Serial No.: 09/529,691 ) Examiner: S. Rawlings  
Filed: August 29, 2000 ) Int'l Filing Date: 22 October 1998  
For: INHIBITION OF TUMOR CELL ADHESION TO TYPE IV COLLAGEN

PRELIMINARY AMENDMENT AND  
RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS

BOX SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Please amend the above-referenced patent application as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 3, line 5, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

C  
- Schnolzer and Kent (M. Schnolzer et al., *Science*, 256, 221-225 (1992)) synthesized all-L and all-D HIV-1 proteases, then examined the chiral specificity of the two enzymes using the substrate 2-aminobenzoyl-Thr-Ile-Nle-Nph-Gln-Arg-NH<sub>2</sub> (where Nph is nitrophenylalanine) (SEQ ID NO:2). The synthetic all-L enzyme cleaved only the all-L, not the all-D, version of 2-aminobenzoyl-Thr-Ile-Nle-Nph-Gln-Arg-NH<sub>2</sub> (SEQ ID NO:2) while the synthetic all-D enzyme cleaved only the all-D substrate. The chiral specificity of enzymes was established by these results.